OncoCyte Corporation which can be found using ticker (OCX) now have 4 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The range between the high target price and low target price is between 0.5 and 0.4 calculating the average target price we see $.45. Given that the stocks previous close was at $.29 this indicates there is a potential upside of 55.2%. There is a 50 day moving average of $.33 and the 200 day MA is $.58. The market cap for the company is $33m. Company Website: https://oncocyte.com
The potential market cap would be $50m based on the market consensus.
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
The company is not paying dividends at this time.
